Loading data for RGNT — first visit, this takes a few seconds.
Regentis Biomaterials Ltd... (RGNT)
NYSE American: RGNT
· Real-Time Price · USD
2.07
-0.03 (-1.43%)
At close: Aug 24, 2026, 3:50 PM
The price, the headline numbers and the latest news, in one place.
Regentis Biomaterials Ltd. (RGNT) Stock Price, Analysis & Data
-1.43% (1D)
No data available
| Bid | 2.04 |
| Market Cap | 14.54M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -13.69M |
| n/a | |
| -24.16 | |
| n/a | |
| n/a | |
| P/B (ttm) | 2.26 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 2.08 |
| Volume | 17,734 |
| Avg. Volume (20D) | 5,409,803 |
| Open | 2.15 |
| Previous Close | 2.10 |
| Day's Range | 1.96 - 2.18 |
| 52-Week Range | 1.23 - 15.50 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About RGNT
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the ...
Industry Medical Instruments & Supplies
Sector Healthcare
IPO Date Dec 4, 2025
Employees n/a
Stock Exchange NYSE American
Ticker Symbol RGNT
Website https://www.regentis.co.il
Financial Performance
In 2025, Regentis Biomaterials's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -13.65M, a decrease of -384.27%.
Financial Statements
